Obesity
Weight management and chronic disease
Half of all Americans report a desire to lose weight, but most attempts to maintain a healthy weight end in failure, and obesity rates continue to rise, increasing the burden on the health system.
3/4
of Americans are overweight or living with obesity1
2.5B
adults overweight globally, including over 890 million living with obesity2
>40
health conditions linked to increased risk due to obesity3
1Source: National Center for Health Statistics, 2021, https://www.cdc.gov/nchs/data/hestat/obesity-adult-17-18/obesity-adult.htm
2Source: World Health Organization, 2025, https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
3Source: American Society for Metabolic and Bariatric Surgery, https://asmbs.org/resources/obesity-in-america/
Obesity is a chronic, relapsing condition that increases the risk of of over 30 health conditions and benefits from medical support
Type 2 diabetes
A growing epidemic
Obesity is a major risk factor for developing prediabetes and diabetes. Approximately 85% of patients with type 2 diabetes are overweight or have obesity. In the United States, around 32 million adults have type 2 diabetes and an estimated 84 million have prediabetes (Source: CDC National Diabetes Statistics Report). Approximately 422 million have type 1 or type 2 diabetes worldwide (Source: 2016 WHO Global Report on Diabetes). A modest 5-7% weight loss has been shown to prevent conversion from prediabetes to diabetes in over 50% of patients. A safe, effective treatment that induces weight loss in people with prediabetes could potentially have a major impact on human health and may also result in tremendous savings for the healthcare system.
85%
of people with type 2 diabetes are overweight or living with obesity1
>88M
Adults in the United States with prediabetes2
1Source: American Journal of Lifestyle Medicine, 2016, https://pmc.ncbi.nlm.nih.gov/articles/PMC6124964/
2Source: Centers for Disease Control and Prevention, https://www.cdc.gov/diabetes/widgets/risktest/about-the-test.html
Weight loss is first-line treatment recommendation for patients with diabetes or pre-diabetes
Inflammatory GI disease
Confronting NAFLD & NASH
Within the GI pathway, the health of the epithelial barrier and mucus layer may play an important role in the treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), as well as diseases involving inflammation of the intestines, such as IBD. NAFLD is considered the most common liver disease in developed nations. NAFLD is defined as the accumulation of excessive fat in the liver in the absence of excessive drinking of alcohol and any secondary cause. An estimated 70-80% of people with obesity have NAFLD. Approximately 20% of patients with NAFLD develop NASH (approximately 5% of the worldwide population). NASH is the second leading indication for liver transplantation and 20-30% of people with NASH progress to cirrhosis/hepatocellular carcinoma.
70-80%
of people living with obesity have non‑alcoholic fatty liver disease (NAFLD)1
NAFLD is strongly associated with multiple serious conditions including obesity, metabolic/insulin resistance syndrome, and dyslipidemia
1Source: The Lancet Gastroenterology and Hepatology, https://pubmed.ncbi.nlm.nih.gov/36400097/
Health resources
For more information please visit
